News

MaxCyte's Innovative Collaboration with Moonlight Bio on T Cell Therapies

MaxCyte's Innovative Collaboration with Moonlight Bio on T Cell Therapies

MaxCyte Forms Strategic Alliance with Moonlight Bio

MaxCyte, Inc. (Nasdaq: MXCT), a pioneering cell-engineering organization, has recently announced a significant collaborative effort with Moonlight Bio, a Seattle-based company focused on pioneering preclinical-stage T cell therapies. This partnership will leverage MaxCyte’s advanced technologies to propel the development of innovative T cell treatments designed specifically for solid tumors.

Technological Edge in T Cell Therapy Development

In the agreement, Moonlight Bio will utilize MaxCyte’s acclaimed Flow Electroporation technology, integrated with the ExPERT platform. These advanced tools are engineered to streamline the development and manufacturing processes of T cell therapies, enabling scalable production to meet the growing demand in the cancer treatment landscape.

“Our collaboration with Moonlight Bio represents a shared vision of advancing cutting-edge gene-edited cell therapies,” stated Maher Masoud, MaxCyte’s President and CEO. The ExPERT platform is recognized globally for its GMP-compliance and regulatory approvals, positioning it as a pivotal asset in optimizing therapeutic outcomes. By facilitating the engineering of cells at an unprecedented scale, MaxCyte’s technologies stand to make a substantial impact on the clinical efficacy of T cell treatments.

Mission-Driven Focus on Solid Tumors

Moonlight Bio is dedicated to overcoming the significant challenges that T cell therapies face, particularly in solid tumors, which are a critical area of concern in cancer treatment. “Solid tumors are notorious for their resilience against existing therapeutic solutions, noting a dire need for more potent intervention methods,” said Jordan Jarjour, Chief Scientific Officer at Moonlight Bio.

With this strategic partnership, Moonlight Bio aims to transform its T cell therapy pipeline to provide effective therapies designed to penetrate these malignant tumors, addressing a key segment of the global cancer burden. Their proactive approach to T cell therapies seeks to generate deeper and more durable responses, giving hope to patients with limited treatment options.

Key Aspects of the Strategic License

Through the Strategic Platform License agreement, Moonlight Bio has secured comprehensive research, clinical, and commercial rights to employ MaxCyte's technology for advancing their T cell therapies. In exchange, MaxCyte stands to gain annual licensing fees along with revenue tied to program developments, establishing a mutually beneficial ecosystem.

About MaxCyte

MaxCyte has long been at the forefront of cell engineering innovation, championing the mission of ‘building better cells together.’ With a commitment that spans over 25 years, MaxCyte's cutting-edge technologies aim to comment on the future of medicine through the development and commercialization of next-generation cell therapies. The Flow Electroporation technology and SeQure gene editing risk assessment services are noteworthy aspects of their offering, designed to enable precise and efficient cell engineering across diverse applications.

Backed by a team of experts providing scientific, technical, and regulatory assistance, MaxCyte empowers researchers worldwide to engineer a variety of cell types and therapeutic payloads, accelerating the path to effective treatments for human health.

Company Contacts

For more information about MaxCyte's advancements in cell engineering or their latest collaborations, you can reach their Investor Relations via:

Investor Relations:
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com

Media Contact:
Oak Street Communications
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com

About Moonlight Bio:
Moonlight Bio is focused on developing enhanced T cell therapies aimed at providing innovative options for cancer patients. They emphasize the importance of generating therapies that can meet and exceed the existing limitations in treating solid tumors. For further inquiries, connect with Moonlight Bio via: info@moonlightbio.us.

Frequently Asked Questions

What is the purpose of the MaxCyte and Moonlight Bio collaboration?

The collaboration aims to develop advanced T cell therapies for solid tumors using MaxCyte's innovative technologies.

What technologies will Moonlight Bio be utilizing from MaxCyte?

Moonlight Bio will deploy MaxCyte’s Flow Electroporation technology and ExPERT platform for their T cell therapy pipeline.

How does this partnership benefit MaxCyte?

MaxCyte stands to gain annual licensing fees and additional program-related revenue through this strategic license agreement.

What is Moonlight Bio's mission?

Moonlight Bio is dedicated to delivering potent T cell therapies that effectively address the challenges associated with treating solid tumors.

How can I learn more about MaxCyte and its technologies?

Detailed information is available on the MaxCyte website and inquiries can be directed to their investor relations team.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 2

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 5

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
D-Wave Faces Legal Questions After CFO Exit and Losses

Updated Category News Views 2

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 4

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
U.S. Green Beret's Mission: Clearing Landmines in Ukraine

Updated Category News Views 1

The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...

Continue Reading
Pizza: The Unlikely Symbol of Universal Togetherness

Updated Category News Views 1

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Continue Reading
Damp or Dry: The Battle for Healthy Air in Colorado

Updated Category News Views 4

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 8

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 3

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 9

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading

Top 5 Most Recently Viewed Articles

Combining Forces: Waters Corporation and BD to Lead Diagnostics

Updated Category News Views 331

Exciting Merger in the Life Sciences Sector In a significant move for the life sciences industry, Waters Corporation (NYSE: WAT) has officially announced its plans to merge with BD (Becton, Dickinson and Company) (NYSE: BDX). This merger aims to create a leading entity in the fields of regulated and high-volume testing. The combination is expected to harness the strengths...

Continue Reading
Citius Oncology Strengthens LYMPHIR Launch with New Partnership

Updated Category News Views 109

Citius Oncology Reinforces Distribution for LYMPHIR Citius Oncology, Inc. (Nasdaq: CTOR), a leading company in oncology therapeutics, has taken a significant step by partnering with Cencora, a global provider of pharmaceutical solutions. The newly signed distribution services agreement is aimed at enhancing commercial infrastructure and ensuring the successful launch of...

Continue Reading
Exploring Growth in Low-Code Development Platforms

Updated Category News Views 242

Surging Growth in Low-Code Development Platforms The demand for low-code development platforms is on the rise, with projected growth from USD 26.30 billion in 2025 up to USD 67.12 billion by 2030, at an impressive CAGR of 20.61%. This surge is primarily fueled by organizations adopting hybrid and multi-cloud strategies, making low-code tools essential for modernizing...

Continue Reading
Foresee Pharmaceuticals Unveils Promising Results for Linvemastat

Updated Category News Views 58

Foresee Pharmaceuticals Announces Groundbreaking Phase 1 Results Foresee Pharmaceuticals (TPEx: 6576) is excited to share notable updates regarding its Phase 1 clinical trial of linvemastat (FP-020), a distinctive and selective oral MMP-12 inhibitor. The trial, focused on assessing safety, tolerability, and pharmacokinetics, has been successfully completed and has...

Continue Reading
Unlocking Spring’s Real Estate Potential with Mistoria Group

Updated Category News Views 302

Why May is the Optimal Time for Real Estate Transactions As the weather warms and spring settles in, the real estate market bursts with activity. Leading property experts suggest that May is the prime month to either buy or sell a home. Mish Liyanage, the CEO of Mistoria Group, emphasizes that emerging market trends provide compelling reasons for homeowners and potential...

Continue Reading